-
-
-
-
-
-
-
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
-
-
-
-
-
-
-
CorMedix Therapeutics Announces Leadership and Board Updates
-
-
-
-
-
-
-
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
-
-
-
-
-
-
-
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
-
-
-
-
-
-
-
CorMedix to acquire Melinta Therapeutics for $300 million
-
-
-
-
-
-
-
CorMedix (CRMD) Announces CMS Revision to NTAP Reimbursement of DefenCath
-
-
-
-
-
-
-
Pre-Open Stock Movers 09/29: (NOVS) (CRMD) (BYND) Higher; (PLL) (BEAM) (AXSM) Lower (more...)
-
1,187,326 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

